Aktis Oncology, Inc.
AKTS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Valuation | |||
| PEG Ratio | 0.00 | 0.00 | 0.00 |
| FCF Yield | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 0.50 | 0.48 | 6.56 |
| Quality | |||
| ROIC | -16.86% | -29.58% | -14.76% |
| Gross Margin | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.34 | 1.05 | 1.01 |
| Growth | |||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 135.24% | -65.27% | 0.00% |
| Safety | |||
| Net Debt / EBITDA | 0.50 | 0.48 | 6.56 |
| Interest Coverage | 0.00 | 0.00 | 0.00 |
| Efficiency | |||
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 |